Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-cash Items (2017 - 2025)

Protalix BioTherapeutics has reported Non-cash Items over the past 9 years, most recently at $5.5 million for Q4 2025.

  • Quarterly results put Non-cash Items at $5.5 million for Q4 2025, up 446.49% from a year ago — trailing twelve months through Dec 2025 was $5.5 million (up 446.49% YoY), and the annual figure for FY2025 was $5.5 million, up 446.49%.
  • Non-cash Items for Q4 2025 was $5.5 million at Protalix BioTherapeutics, up from $1.0 million in the prior quarter.
  • Over the last five years, Non-cash Items for PLX hit a ceiling of $5.5 million in Q4 2025 and a floor of $961940.0 in Q4 2021.
  • Median Non-cash Items over the past 5 years was $1.2 million (2022), compared with a mean of $2.2 million.
  • Biggest five-year swings in Non-cash Items: surged 800.06% in 2021 and later crashed 61.54% in 2024.
  • Protalix BioTherapeutics' Non-cash Items stood at $961940.0 in 2021, then increased by 24.75% to $1.2 million in 2022, then surged by 116.67% to $2.6 million in 2023, then crashed by 61.54% to $1.0 million in 2024, then skyrocketed by 446.49% to $5.5 million in 2025.
  • The last three reported values for Non-cash Items were $5.5 million (Q4 2025), $1.0 million (Q4 2024), and $2.6 million (Q4 2023) per Business Quant data.